JULIA BERMAN: Open Payments
NPI 1780202473 · PASADENA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,991 in 168 payments from 21 companies in 2025. Trend: 2023 $2,795 · 2024 $2,970 · 2025 $4,991
Food & beverage: $4,991
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 9 | $721 |
| ABBVIE INC. | 30 | $682 |
| UCB, Inc. | 27 | $677 |
| Galderma Laboratories, L.P. | 28 | $489 |
| Incyte Corporation | 11 | $424 |
| LEO Pharma Inc. | 6 | $344 |
| Arcutis Biotherapeutics, Inc. | 11 | $307 |
| Botanix SB Inc | 8 | $224 |
| Janssen Biotech, Inc. | 6 | $217 |
| GENZYME CORPORATION | 5 | $177 |
Products named: DUPIXENT, Bimzelx, OPZELURA, RINVOQ, SKYRIZI, Zoryve, NEMLUVIO, SOFDRA.
Industry payments across CA — which companies pay providers there.
